{"transactions":[{"id":751314,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-03T22:06:47.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":11182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders."}],"balance_after":11182,"derivative":{"exercise_price":5.43,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":11182},"source":{"system":"sec-edgar","filing":"0001523522-26-000007","document":"form4-06032026_100643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000152352226000007/form4-06032026_100643.xml","form_type":"4"}},{"id":751313,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:06:47.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":8720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders."}],"balance_after":8720,"source":{"system":"sec-edgar","filing":"0001523522-26-000007","document":"form4-06032026_100643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000152352226000007/form4-06032026_100643.xml","form_type":"4"}},{"id":909596,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":359255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359255},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909595,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":548067,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909594,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":548067,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909593,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1690230,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1690230},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":911482,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":2059573,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359255},"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911481,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":3142015,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911480,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":3142015,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911479,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":9689922,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1690230},"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911478,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":16,"value":2640000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3310619,"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911477,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":359255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3145619,"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911476,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":548067,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2786364,"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911475,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":548067,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2238297,"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":911474,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T23:09:42.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1690230,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1690230,"source":{"system":"sec-edgar","filing":"0001193125-26-045029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526045029/ownership.xml","form_type":"4"}},{"id":912219,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":2059573,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359255},"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912218,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":3142015,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912217,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":3142015,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912216,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":9689922,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1690230},"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912215,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":16,"value":2640000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3310619,"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912214,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":359255,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3145619,"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912213,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":548067,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2786364,"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912212,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":548067,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2238297,"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":912211,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":67058,"kind":"organization","name":"Vensana Capital I GP, LLC","position":1,"cik":"0001854073","reported_name":"Vensana Capital I GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67059,"kind":"organization","name":"Vensana Capital I, L.P.","position":2,"cik":"0001757539","reported_name":"Vensana Capital I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":3,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67060,"kind":"person","name":"Klein Peter Justin","position":4,"cik":"0001608710","reported_name":"Klein Peter Justin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-10T18:08:58.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1690230,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1690230,"source":{"system":"sec-edgar","filing":"0001193125-26-045028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854073/000119312526045028/ownership.xml","form_type":"4"}},{"id":914139,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T21:54:40.000Z","date":"2026-02-05","kind":"grant","planned":false,"acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). \"Date of Grant\" shall mean February 5, 2026."}],"balance_after":27400,"derivative":{"exercise_price":16,"expiration_date":"2036-02-05","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001523522-26-000004","document":"form4-02092026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000152352226000004/form4-02092026_090237.xml","form_type":"4"}},{"id":1121089,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T21:35:50.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":19554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders."}],"balance_after":19554,"derivative":{"exercise_price":6.76,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":19554},"source":{"system":"sec-edgar","filing":"0001415889-25-015816","document":"form4-06052025_090637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000141588925015816/form4-06052025_090637.xml","form_type":"4"}},{"id":1142309,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:46:37.000Z","date":"2025-05-15","kind":"purchase","planned":false,"acquired":true,"shares":10966,"price":5.4528,"value":59795.4048,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.37 to $5.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1910134,"source":{"system":"sec-edgar","filing":"0000950170-25-074682","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000095017025074682/ownership.xml","form_type":"4"}},{"id":1148973,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-14T21:27:07.000Z","date":"2025-05-14","kind":"purchase","planned":false,"acquired":true,"shares":61200,"price":5.2347,"value":320363.64,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.07 to $5.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1899168,"source":{"system":"sec-edgar","filing":"0000950170-25-071629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000095017025071629/ownership.xml","form_type":"4"}},{"id":1148972,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-14T21:27:07.000Z","date":"2025-05-13","kind":"purchase","planned":false,"acquired":true,"shares":101413,"price":5.2884,"value":536312.5092,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $5.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1837968,"source":{"system":"sec-edgar","filing":"0000950170-25-071629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000095017025071629/ownership.xml","form_type":"4"}},{"id":1148971,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-14T21:27:07.000Z","date":"2025-05-12","kind":"purchase","planned":false,"acquired":true,"shares":25200,"price":4.7885,"value":120670.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.65 to $4.845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1736555,"source":{"system":"sec-edgar","filing":"0000950170-25-071629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000095017025071629/ownership.xml","form_type":"4"}},{"id":1486445,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:18:52.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":27250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person's Form 4 filed on June 6, 2024 inadvertently understated the reporting person's stock options granted by 6,289."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests on the earlier of June 4, 2025 or the Issuer's 2025 annual meeting of stockholders."}],"balance_after":27250,"derivative":{"exercise_price":6.49,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":27250},"source":{"system":"sec-edgar","filing":"0001415889-24-016039","document":"form4a-06072024_090647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000141588924016039/form4a-06072024_090647.xml","form_type":"4/A","original_submission_date":"2024-06-06"}},{"id":1488197,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-06T23:05:12.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":20961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 4, 2025 or the Issuer's 2025 annual meeting of stockholders."}],"balance_after":20961,"derivative":{"exercise_price":6.49,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":20961},"source":{"system":"sec-edgar","filing":"0001415889-24-015846","document":"form4-06062024_110608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000141588924015846/form4-06062024_110608.xml","form_type":"4"}},{"id":1863672,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-07T20:12:05.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":12012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 5, 2024 or the Issuer's 2024 annual meeting of stockholders."}],"balance_after":12012,"derivative":{"exercise_price":12.33,"expiration_date":"2033-06-04","underlying":"Common Stock","underlying_shares":12012},"source":{"system":"sec-edgar","filing":"0001415889-23-009357","document":"form4-06072023_080657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000141588923009357/form4-06072023_080657.xml","form_type":"4"}},{"id":1874318,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2023-05-30T20:35:58.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":false,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2982},"source":{"system":"sec-edgar","filing":"0001127602-23-017037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760223017037/form4.xml","form_type":"4"}},{"id":1874317,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-30T20:35:58.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":true,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":61479,"source":{"system":"sec-edgar","filing":"0001127602-23-017037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760223017037/form4.xml","form_type":"4"}},{"id":1882208,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-22T16:09:22.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":2412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting."}],"balance_after":58497,"source":{"system":"sec-edgar","filing":"0001127602-23-016392","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760223016392/form4.xml","form_type":"4"}},{"id":2237494,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T20:36:50.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":26985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 7, 2023 or the Issuer's 2023 annual meeting of stockholders."}],"balance_after":26985,"derivative":{"exercise_price":6.76,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":26985},"source":{"system":"sec-edgar","filing":"0001415889-22-006365","document":"form4-06092022_010640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000141588922006365/form4-06092022_010640.xml","form_type":"4"}},{"id":2252814,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2022-05-27T20:33:55.000Z","date":"2022-05-27","kind":"exercise","acquired":false,"shares":2983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."}],"balance_after":2982,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2983},"source":{"system":"sec-edgar","filing":"0001127602-22-015870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760222015870/form4.xml","form_type":"4"}},{"id":2252813,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-27T20:33:55.000Z","date":"2022-05-27","kind":"exercise","acquired":true,"shares":2983,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56085,"source":{"system":"sec-edgar","filing":"0001127602-22-015870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760222015870/form4.xml","form_type":"4"}},{"id":2252812,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-27T20:33:55.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":2420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting."}],"balance_after":53102,"source":{"system":"sec-edgar","filing":"0001127602-22-015870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000112760222015870/form4.xml","form_type":"4"}},{"id":2255006,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T22:13:40.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":8070,"price":5.0498,"value":40751.886,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.02 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1711355,"source":{"system":"sec-edgar","filing":"0000899243-22-019805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322019805/doc4.xml","form_type":"4"}},{"id":2259701,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T23:56:57.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":4432,"price":5.0396,"value":22335.5072,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.01 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1703285,"source":{"system":"sec-edgar","filing":"0000899243-22-019287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322019287/doc4.xml","form_type":"4"}},{"id":2259700,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T23:56:57.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":13387,"price":5.0354,"value":67408.8998,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1698853,"source":{"system":"sec-edgar","filing":"0000899243-22-019287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322019287/doc4.xml","form_type":"4"}},{"id":2259699,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T23:56:57.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":10976,"price":5.038,"value":55297.088,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.005 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1685466,"source":{"system":"sec-edgar","filing":"0000899243-22-019287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322019287/doc4.xml","form_type":"4"}},{"id":2280653,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T20:33:16.000Z","date":"2022-05-05","kind":"purchase","acquired":true,"shares":3992,"price":5.996,"value":23936.032,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1674490,"source":{"system":"sec-edgar","filing":"0000899243-22-016823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322016823/doc4.xml","form_type":"4"}},{"id":2280652,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T20:33:16.000Z","date":"2022-05-04","kind":"purchase","acquired":true,"shares":25503,"price":5.9899,"value":152760.4197,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.91 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1670498,"source":{"system":"sec-edgar","filing":"0000899243-22-016823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322016823/doc4.xml","form_type":"4"}},{"id":2280651,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T20:33:16.000Z","date":"2022-05-03","kind":"purchase","acquired":true,"shares":32809,"price":5.9972,"value":196762.1348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1644995,"source":{"system":"sec-edgar","filing":"0000899243-22-016823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322016823/doc4.xml","form_type":"4"}},{"id":2286343,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-02T21:34:26.000Z","date":"2022-05-02","kind":"purchase","acquired":true,"shares":41988,"price":5.9701,"value":250672.5588,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1612186,"source":{"system":"sec-edgar","filing":"0000899243-22-016135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322016135/doc4.xml","form_type":"4"}},{"id":2286342,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-02T21:34:26.000Z","date":"2022-04-28","kind":"purchase","acquired":true,"shares":100,"price":5.97,"value":597.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1570198,"source":{"system":"sec-edgar","filing":"0000899243-22-016135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322016135/doc4.xml","form_type":"4"}},{"id":2368603,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T22:17:18.000Z","date":"2022-02-24","kind":"purchase","acquired":true,"shares":3400,"price":8.2381,"value":28009.54,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.00 to $8.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1570098,"source":{"system":"sec-edgar","filing":"0000899243-22-008108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322008108/doc4.xml","form_type":"4"}},{"id":2377928,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-23T22:36:54.000Z","date":"2022-02-23","kind":"purchase","acquired":true,"shares":38200,"price":8.0404,"value":307143.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.99 to $8.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1566698,"source":{"system":"sec-edgar","filing":"0000899243-22-007418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322007418/doc4.xml","form_type":"4"}},{"id":2377927,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-23T22:36:54.000Z","date":"2022-02-22","kind":"purchase","acquired":true,"shares":40008,"price":7.9399,"value":317659.5192,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.84 to $8.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1528498,"source":{"system":"sec-edgar","filing":"0000899243-22-007418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322007418/doc4.xml","form_type":"4"}},{"id":2377926,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-23T22:36:54.000Z","date":"2022-02-18","kind":"purchase","acquired":true,"shares":26659,"price":7.9233,"value":211227.2547,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.54 to $8.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1488490,"source":{"system":"sec-edgar","filing":"0000899243-22-007418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000089924322007418/doc4.xml","form_type":"4"}},{"id":2644044,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series G Preferred Stock","published_at":"2021-07-02T21:03:02.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":23125000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series G Convertible Preferred Stock automatically converted into shares of common stock at a rate of 1-for-0.0632143218."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of common stock at the then-appliable conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of common stock at the then-appliable conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1461831},"source":{"system":"sec-edgar","filing":"0001179110-21-007340","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000117911021007340/edgar.xml","form_type":"4"}},{"id":2644043,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T21:03:02.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":1461831,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series G Convertible Preferred Stock automatically converted into shares of common stock at a rate of 1-for-0.0632143218."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares."}],"balance_after":1461831,"source":{"system":"sec-edgar","filing":"0001179110-21-007340","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000117911021007340/edgar.xml","form_type":"4"}},{"id":2647377,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T21:32:16.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":10382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders."}],"balance_after":10382,"derivative":{"exercise_price":18,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":10382},"source":{"system":"sec-edgar","filing":"0001179110-21-007271","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235912/000117911021007271/edgar.xml","form_type":"4"}},{"id":2690830,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-05-28T23:39:12.000Z","date":"2021-05-27","kind":"exercise","acquired":false,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."}],"balance_after":5965,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2982},"source":{"system":"sec-edgar","filing":"0001562180-21-003847","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000156218021003847/primarydocument.xml","form_type":"4"}},{"id":2690829,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T23:39:12.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":1380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs granted on May 27, 2021 to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2022 annual meeting."}],"balance_after":50682,"source":{"system":"sec-edgar","filing":"0001562180-21-003847","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000156218021003847/primarydocument.xml","form_type":"4"}},{"id":2690828,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T23:39:12.000Z","date":"2021-05-27","kind":"exercise","acquired":true,"shares":2982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") which represent a contingent right to receive one share of common stock for each RSU.  1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years."}],"balance_after":49302,"source":{"system":"sec-edgar","filing":"0001562180-21-003847","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000156218021003847/primarydocument.xml","form_type":"4"}},{"id":2788789,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-12","kind":"sale","acquired":false,"shares":206,"price":120,"value":24720.0,"ownership":{"direct":true},"balance_after":46320,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2788788,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-11","kind":"other","acquired":false,"shares":3596,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"Versant Side Fund\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2788787,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-11","kind":"other","acquired":true,"shares":7955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures IV GP."}],"balance_after":46526,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2788786,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-11","kind":"other","acquired":false,"shares":147021,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2788785,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-11","kind":"other","acquired":true,"shares":147021,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":147021,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2788784,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T23:06:26.000Z","date":"2021-03-11","kind":"other","acquired":false,"shares":570957,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"Versant IV\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant IV. Versant Ventures IV, LLC (\"Versant Ventures IV GP\") is the general partner of Versant IV. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321011699/doc4.xml","form_type":"4"}},{"id":2905591,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-15T21:28:20.000Z","date":"2021-01-13","kind":"other","acquired":false,"shares":5395,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"Versant Side Fund\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":3596,"source":{"system":"sec-edgar","filing":"0000899243-21-002186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321002186/doc4.xml","form_type":"4"}},{"id":2905590,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-15T21:28:20.000Z","date":"2021-01-13","kind":"other","acquired":true,"shares":11933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures IV GP."}],"balance_after":38571,"source":{"system":"sec-edgar","filing":"0000899243-21-002186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321002186/doc4.xml","form_type":"4"}},{"id":2905589,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-15T21:28:20.000Z","date":"2021-01-13","kind":"other","acquired":false,"shares":220532,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-002186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321002186/doc4.xml","form_type":"4"}},{"id":2905588,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-15T21:28:20.000Z","date":"2021-01-13","kind":"other","acquired":true,"shares":220532,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":220532,"source":{"system":"sec-edgar","filing":"0000899243-21-002186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321002186/doc4.xml","form_type":"4"}},{"id":2905587,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-15T21:28:20.000Z","date":"2021-01-13","kind":"other","acquired":false,"shares":856437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"Versant IV\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant IV. Versant Ventures IV, LLC (\"Versant Ventures IV GP\") is the general partner of Versant IV. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":570957,"source":{"system":"sec-edgar","filing":"0000899243-21-002186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321002186/doc4.xml","form_type":"4"}},{"id":2914747,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T23:14:25.000Z","date":"2021-01-04","kind":"other","acquired":false,"shares":5395,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"Versant Side Fund\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":8991,"source":{"system":"sec-edgar","filing":"0000899243-21-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321000738/doc4.xml","form_type":"4"}},{"id":2914746,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T23:14:25.000Z","date":"2021-01-04","kind":"other","acquired":true,"shares":11932,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures IV GP."}],"balance_after":26638,"source":{"system":"sec-edgar","filing":"0000899243-21-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321000738/doc4.xml","form_type":"4"}},{"id":2914745,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T23:14:25.000Z","date":"2021-01-04","kind":"other","acquired":false,"shares":220530,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321000738/doc4.xml","form_type":"4"}},{"id":2914744,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T23:14:25.000Z","date":"2021-01-04","kind":"other","acquired":true,"shares":220530,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":220530,"source":{"system":"sec-edgar","filing":"0000899243-21-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321000738/doc4.xml","form_type":"4"}},{"id":2914743,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T23:14:25.000Z","date":"2021-01-04","kind":"other","acquired":false,"shares":856437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"Versant IV\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant IV. Versant Ventures IV, LLC (\"Versant Ventures IV GP\") is the general partner of Versant IV. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":1427394,"source":{"system":"sec-edgar","filing":"0000899243-21-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924321000738/doc4.xml","form_type":"4"}},{"id":2956282,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:45:58.000Z","date":"2020-12-02","kind":"other","acquired":false,"shares":2654,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"Versant Side Fund\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":14386,"source":{"system":"sec-edgar","filing":"0000899243-20-032774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320032774/doc4.xml","form_type":"4"}},{"id":2956281,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:45:58.000Z","date":"2020-12-02","kind":"other","acquired":true,"shares":5869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Venture IV GP."}],"balance_after":14706,"source":{"system":"sec-edgar","filing":"0000899243-20-032774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320032774/doc4.xml","form_type":"4"}},{"id":2956280,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:45:58.000Z","date":"2020-12-02","kind":"other","acquired":false,"shares":108490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-032774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320032774/doc4.xml","form_type":"4"}},{"id":2956279,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:45:58.000Z","date":"2020-12-02","kind":"other","acquired":true,"shares":108490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":108490,"source":{"system":"sec-edgar","filing":"0000899243-20-032774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320032774/doc4.xml","form_type":"4"}},{"id":2956278,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:45:58.000Z","date":"2020-12-02","kind":"other","acquired":false,"shares":421331,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"Versant IV\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant IV. Versant Ventures IV, LLC (\"Versant Ventures IV GP\") is the general partner of Versant IV. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":2283831,"source":{"system":"sec-edgar","filing":"0000899243-20-032774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320032774/doc4.xml","form_type":"4"}},{"id":2972743,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T02:36:25.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":8837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Venture IV GP."}],"balance_after":8837,"source":{"system":"sec-edgar","filing":"0000899243-20-031774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320031774/doc4.xml","form_type":"4"}},{"id":2972742,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T02:36:25.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":18925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. (\"Versant Side Fund\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Versant Side Fund. Versant Ventures IV GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":17040,"source":{"system":"sec-edgar","filing":"0000899243-20-031774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320031774/doc4.xml","form_type":"4"}},{"id":2972741,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T02:36:25.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":164825,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320031774/doc4.xml","form_type":"4"}},{"id":2972740,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T02:36:25.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":164825,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Ventures IV GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Ventures IV GP. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":164825,"source":{"system":"sec-edgar","filing":"0000899243-20-031774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320031774/doc4.xml","form_type":"4"}},{"id":2972739,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T02:36:25.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":3004415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. (\"Versant IV\"), to its partners, pursuant to a Rule 10b5-1 distribution plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant IV. Versant Ventures IV, LLC (\"Versant Ventures IV GP\") is the general partner of Versant IV. The Reporting Person is a managing member of Versant Ventures IV GP and may be deemed to share voting and dispositive power over the shares held by Versant IV; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":2705162,"source":{"system":"sec-edgar","filing":"0000899243-20-031774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000089924320031774/doc4.xml","form_type":"4"}},{"id":3133266,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-05-27T22:35:25.000Z","date":"2020-05-27","kind":"exercise","acquired":false,"shares":977058,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Includes (i) 970,942 shares held of record by Versant Capital and (ii) 6,116 shares held of record by Versant Side"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant Capital and Versant Side. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stoc","underlying_shares":977058},"source":{"system":"sec-edgar","filing":"0001209191-20-032411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000120919120032411/doc4.xml","form_type":"4"}},{"id":3133265,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-05-27T22:35:25.000Z","date":"2020-05-27","kind":"exercise","acquired":false,"shares":1197058,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (i) 1,189,565 shares held of record by Versant Capital and (ii) 7,493 shares held of record by Versant Side."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant Capital and Versant Side. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1197058},"source":{"system":"sec-edgar","filing":"0001209191-20-032411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000120919120032411/doc4.xml","form_type":"4"}},{"id":3133264,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-05-27T22:35:25.000Z","date":"2020-05-27","kind":"exercise","acquired":false,"shares":3571426,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes (i) 3,549,070 shares held of record by Versant Venture Capital IV, L.P. (\"Versant Capital\") and (ii) 22,356 shares held of record by Versant Side Fund IV, L.P. (\"Versant Side\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant Capital and Versant Side. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3571426},"source":{"system":"sec-edgar","filing":"0001209191-20-032411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000120919120032411/doc4.xml","form_type":"4"}},{"id":3133263,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-05-27T22:35:25.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":8947,"price":19,"value":169993.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 27, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 27, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 27, 2020."}],"balance_after":8947,"derivative":{"underlying":"Common Stock","underlying_shares":8947},"source":{"system":"sec-edgar","filing":"0001209191-20-032411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000120919120032411/doc4.xml","form_type":"4"}},{"id":3133262,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-27T22:35:25.000Z","date":"2020-05-27","kind":"exercise","acquired":true,"shares":5745542,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes (i) 3,549,070 shares held of record by Versant Venture Capital IV, L.P. (\"Versant Capital\") and (ii) 22,356 shares held of record by Versant Side Fund IV, L.P. (\"Versant Side\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (i) 1,189,565 shares held of record by Versant Capital and (ii) 7,493 shares held of record by Versant Side."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Includes (i) 970,942 shares held of record by Versant Capital and (ii) 6,116 shares held of record by Versant Side"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant Capital and Versant Side. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5745542,"source":{"system":"sec-edgar","filing":"0001209191-20-032411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000120919120032411/doc4.xml","form_type":"4"}}]}